Collegium Pharmaceutical (NASDAQ:COLL) Trading Up 2.8% – What’s Next?

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rose 2.8% during trading on Wednesday . The company traded as high as $30.00 and last traded at $29.97. Approximately 25,883 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 368,973 shares. The stock had previously closed at $29.14.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Stock Up 14.1 %

The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a 50 day moving average of $30.61 and a two-hundred day moving average of $34.05. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 14.33 and a beta of 0.82.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its position in Collegium Pharmaceutical by 2.8% in the second quarter. Rhumbline Advisers now owns 107,364 shares of the specialty pharmaceutical company’s stock valued at $3,457,000 after buying an additional 2,966 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Collegium Pharmaceutical by 172.7% during the 2nd quarter. TD Asset Management Inc now owns 15,000 shares of the specialty pharmaceutical company’s stock valued at $483,000 after acquiring an additional 9,500 shares in the last quarter. Quest Partners LLC grew its position in Collegium Pharmaceutical by 186.0% during the 2nd quarter. Quest Partners LLC now owns 18,827 shares of the specialty pharmaceutical company’s stock worth $606,000 after acquiring an additional 12,244 shares during the last quarter. Choreo LLC acquired a new position in Collegium Pharmaceutical in the 2nd quarter worth about $396,000. Finally, American Century Companies Inc. raised its position in Collegium Pharmaceutical by 8.8% in the second quarter. American Century Companies Inc. now owns 99,808 shares of the specialty pharmaceutical company’s stock valued at $3,214,000 after purchasing an additional 8,097 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.